التفاصيل البيبلوغرافية
| العنوان: |
Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom. |
| المؤلفون: |
Kaji, Furqaan A., Martinez‐Calle, Nicolas, Bishton, Mark J., Figueroa, Rocio, Adlington, Joanne, O'Donoghue, Michael, Smith, Stuart, Byrne, Paul, Paine, Simon, Sovani, Vishakha, Auer, Dorothee, James, Eleanor, Bessell, Eric M., Grainge, Matthew J., Fox, Christopher P. |
| المصدر: |
British Journal of Haematology; Nov2021, Vol. 195 Issue 4, p561-570, 10p |
| مصطلحات موضوعية: |
SURVIVAL rate, CENTRAL nervous system, DIAGNOSIS, OVERALL survival, STEM cell transplantation, CENTRAL nervous system tumors |
| مصطلحات جغرافية: |
UNITED Kingdom |
| مستخلص: |
Summary: Observational studies with long‐term follow‐up of patients with primary central nervous system lymphoma (PCNSL) are scarce. Patient data over a period of four decades were retrospectively analysed from databases at Nottingham University Hospitals Trust, UK. The cohort was delineated by two distinct therapeutic eras; the first from 01/01/1982 to 31/12/2010 (n = 147) and the second 01/01/2011 to 31/07/2020 (n = 125). The median age at diagnosis was significantly older in the second era compared to the first (69 and 65 years respectively, P = 0·003). The 3‐, 6‐ and 12‐month overall survival (OS) rates in the second era were significantly higher compared to the first, at 85%, 77%, 62% versus 56%, 49%, 38% respectively (log‐rank test P < 0·0001). On multivariate analysis, high‐dose methotrexate (HD‐MTX)‐based induction protocols employed in the second era were associated with improved OS compared to those used in the first [hazard ratio (HR) 0·40, 95% confidence interval (CI) 0·28–0·57]. Within the second era, superior OS rates were seen with the use of intensive HD‐MTX protocols (including consolidation with high‐dose chemotherapy and autologous stem cell transplantation) compared to non‐intensive HD‐MTX schedules (HR 0·47, 95% CI 0·22–0·99). Initiating chemotherapy within 14 days of biopsy and use of rituximab were independently associated with improved OS and progression‐free survival during the second era. These data suggest that prompt treatment initiation and use of intensive HD‐MTX‐ and rituximab‐based protocols have resulted in improved survival outcomes for patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
